← Leaderboards
John Alam
Eip Pharma, Inc.
$10,536,018
Attributed
$21,072,036
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.3M · FY2023–25$10M$7.5M$5M$2.5M$0
'23
'24
'25
Funding mix
By agency
NIH$21,072,036 · 1
By mechanism
R01$21,072,036 · 1
Top collaborators
- James E Galvin4 shared
Others in their field
Other Rising Stars on “Admission Activity”
- Gary Lessing · Inovodel, Inc.$2,946,822
- Lorraine I Kelley-Quon · Children'S Hospital Of Los Angeles$2,495,528
- Joseph Shapiro · National Bureau Of Economic Research$2,440,931
- Katherine Hoops · Johns Hopkins University$2,401,338
- Timothy William Dunn · Duke University$2,387,866
- Shanina C Knighton · Case Western Reserve University$2,370,083
Research focus
Admission ActivityCognitiveAggressive BehaviorAdverse EventAlzheimer&AposCognitionAttentionBasal ForebrainBasal Forebrain Cholinergic NeuronsAgitationBehavioral SymptomsBiological AvailabilityAmericanAffectCessation Of LifeCholinergicCholinesterase InhibitorsClinical Dementia Rating ScaleClinical DevelopmentClinical EfficacyClinically RelevantClinical ResearchClinical TrialsCollection
Grant awards (4)
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)$6,072,987
R01 · FY2025 · AG · contact PI
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)$8,066,994
R01 · FY2024 · AG · contact PI
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)$250,000
R01 · FY2024 · AG · contact PI
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)$6,682,055
R01 · FY2023 · AG · contact PI